{"product_id":"cigna-bcg-matrix","title":"Cigna Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCigna’s BCG Matrix preview highlights which business lines are fueling growth, which generate steady cash, and which may need reevaluation as healthcare shifts; it’s a concise snapshot of portfolio strength and strategic risk. This brief only scratches the surface—purchase the full BCG Matrix to get quadrant-by-quadrant placements, data-driven recommendations, and a ready-to-use Word + Excel package that guides capital allocation and product strategy with actionable clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccredo Specialty Pharmacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAccredo Specialty Pharmacy remains a Star in Cigna’s BCG Matrix through late 2025, serving ~430,000 patients and handling specialty spend of roughly $12.5 billion in 2024–25, up 9% year-over-year; growth is driven by complex biologics and gene therapies. The unit reinvests ~15–18% of revenue into clinical services, cold-chain logistics, and digital adherence tools to protect a market share near 28% in U.S. specialty dispensing. Significant pipeline opportunity exists: orphan drug approvals rose 22% in 2024, and Accredo’s targeted programs aim to capture higher-margin infusion and specialty injectables. Continued capital deployment and integrated care models sustain leadership as specialty drug spend is projected to hit $250 billion by 2028.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilar Distribution Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCigna’s Evernorth benefits from a biosimilar market set to reach US$50–60B by 2025, making Biosimilar Distribution Services a Star in the BCG matrix as volume and revenue grow rapidly.\u003c\/p\u003e\n\u003cp\u003eBy shifting utilization to biosimilars—price discounts often 20–40%—Evernorth captures higher gross margins; Cigna reported pharmacy margin lift of ~150–250 bps in 2024 from biosimilar uptake.\u003c\/p\u003e\n\u003cp\u003eTo defend first-to-market share in key classes (oncology, autoimmune), this segment needs continuous clinical support and targeted marketing; Evernorth spends an estimated low- to mid-single-digit percent of segment sales on provider outreach and education.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Expat Health Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCigna Global Health Benefits’ International Expat Health Services is a cash cow in the BCG matrix: it reported ~10% revenue growth in 2024 and contributes roughly 18% of Cigna’s global health revenue, driven by multinational hiring and 8% annual expansion of the expat insurance niche versus 3% domestic markets. It holds a high market share in specialized expat plans and remains a vital growth engine, needing localized capex and compliance spend to manage 100+ regulatory jurisdictions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Virtual Care Delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe integration of MDLive into Evernorth has made Integrated Virtual Care Delivery a star in Cigna’s BCG Matrix, with Evernorth virtual visits rising ~45% YoY to 12.4 million in 2025 and revenue contribution up by ~$300M vs 2023.\u003c\/p\u003e\n\u003cp\u003eAs hybrid care becomes standard by 2026, Cigna gains share in digital-first primary and urgent care—Evernorth claims ~18% share of US virtual primary care visits in 2025, ahead of most peers.\u003c\/p\u003e\n\u003cp\u003eSustained investment in telehealth platforms, AI triage, and a 60k+ provider network remains essential to fend off tech-native competitors and protect margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eVisits: 12.4M in 2025 (~+45% YoY)\u003c\/li\u003e\n\u003cli\u003eRevenue lift: +$300M vs 2023\u003c\/li\u003e\n\u003cli\u003eMarket share: ~18% US virtual primary care (2025)\u003c\/li\u003e\n\u003cli\u003eProvider network: 60,000+ clinicians\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvernorth Data Analytics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEvernorth Data Analytics is a Star in Cigna’s BCG matrix: predictive health analytics and health‑services data grew ~22% YoY in 2024, driving high-margin external contracts with payers and governments focused on lowering total cost of care.\u003c\/p\u003e\n\u003cp\u003eThe unit consumes R\u0026amp;D cash—Evernorth invested ~$350M in analytics R\u0026amp;D in 2024—but is essential to retain market share in the data-driven healthcare economy and to secure long-term revenue streams from value‑based care programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue growth ~22%\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D spend ~$350M (2024)\u003c\/li\u003e\n\u003cli\u003eHigh-margin external contracts with government and payers\u003c\/li\u003e\n\u003cli\u003eKey to lowering total cost of care via predictive models\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvernorth Growth Engines: Accredo Scale, Biosimilars Upside, Virtual Care \u0026amp; Analytics Momentum\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: Accredo (430k patients; $12.5B spend; ~28% share; reinvest 15–18%); Evernorth Biosimilars (market $50–60B by 2025; margin lift 150–250 bps); Integrated Virtual Care (12.4M visits 2025; +$300M revenue; 18% share); Evernorth Analytics (22% growth 2024; $350M R\u0026amp;D).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003eKey 2024–25 metrics\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccredo\u003c\/td\u003e\n\u003ctd\u003e430k pts; $12.5B; 28%; reinvest 15–18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilars\u003c\/td\u003e\n\u003ctd\u003e$50–60B market; +150–250bps margin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVirtual Care\u003c\/td\u003e\n\u003ctd\u003e12.4M visits; +$300M; 18% share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnalytics\u003c\/td\u003e\n\u003ctd\u003e22% growth; $350M R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eIn-depth BCG Matrix of Cigna: strategic insights for Stars, Cash Cows, Question Marks, and Dogs, with investment, hold, divest recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Cigna BCG Matrix placing each business unit in a quadrant for fast strategic clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpress Scripts PBM\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExpress Scripts PBM, Cigna’s primary cash cow, generated roughly $30–35 billion in annual revenue and sustained high operating margins in 2024, reflecting its dominant ~30%+ share of the US PBM market and scale-driven gross-to-net advantages.\u003c\/p\u003e\n\u003cp\u003eIts bargaining power with drug makers and payer contracts produces predictable free cash flow—about $8–10 billion in 2024—which Cigna channels into digital health and specialty pharmacy growth initiatives like Accredo and Evernorth investments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUS Commercial Employer Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCigna’s US commercial employer market is a cash cow: employer-sponsored plans generated about $40.2 billion in premium revenue in 2024, delivering steady margin and ~90% client retention among large accounts as of Q4 2024. This mature segment requires relatively low incremental capital versus Cigna’s digital-health growth bets, funding investments and returning free cash flow to the company.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDental and Vision Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDental and vision are mature markets where Cigna (Cigna Group, NYSE: CI) held ~12–14% US dental market share and ~8–10% vision share in 2024, yielding high gross margins (estimated 25–35%) and low acquisition costs. These lines generated steady annual cashflow—roughly $1.2–1.5 billion in operating profit contribution in 2024—and need minimal promotion, making them milkable assets for cross-selling medical and supplemental plans.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdministrative Services Only (ASO)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe ASO (Administrative Services Only) unit lets Cigna earn steady fee income for administering employer health plans while avoiding medical risk; in 2024 ASO contributed roughly $3.8 billion in revenue and maintained margins near 9%, per Cigna’s 2024 10-K.\u003c\/p\u003e\n\u003cp\u003eThis mature, low-risk segment shows stable cash flow through economic cycles, backing Cigna’s dividend (2024 annual dividend $3.90 per share) and debt service (net debt\/EBITDA ~2.6x in FY2024).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSteady fees, no medical risk\u003c\/li\u003e\n\u003cli\u003e2024 revenue ≈ $3.8B, ~9% margin\u003c\/li\u003e\n\u003cli\u003eSupports dividends $3.90\/yr (2024)\u003c\/li\u003e\n\u003cli\u003eHelps maintain net debt\/EBITDA ~2.6x (FY2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare Supplement Plans\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMedicare Supplement plans (Medigap) are a stable, mature cash cow for Cigna, delivering predictable premiums and low capital needs versus the volatile Medicare Advantage market; in 2024 Medigap enrollment nationally rose ~1.8% to 10.5 million, supporting steady market share.\u003c\/p\u003e\n\u003cp\u003eThe unit benefits from the aging U.S. population—65+ projected at 54 million in 2025—and produced high-margin cash flow in 2024, funding R\u0026amp;D and new market entries without heavy capital spending.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow capital intensity, high margin\u003c\/li\u003e\n\u003cli\u003eSupports funding for experimental health tech\u003c\/li\u003e\n\u003cli\u003eStable enrollment growth (~1.8% national, 2024)\u003c\/li\u003e\n\u003cli\u003eBacked by 65+ cohort ~54M in 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStable 2024 cash flow: PBM $8–10B FCF, $40B employer premiums, $3.90 dividend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExpress Scripts PBM, US commercial employer plans, dental\/vision, ASO, and Medigap together generated predictable free cash flow in 2024—PBM revenue $30–35B (FCF ~$8–10B), employer premiums $40.2B, dental\/vision operating profit $1.2–1.5B, ASO revenue $3.8B (≈9% margin), supporting dividend $3.90\/share and net debt\/EBITDA ~2.6x.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBusiness\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBM (Express Scripts)\u003c\/td\u003e\n\u003ctd\u003e$30–35B rev; FCF $8–10B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployer plans\u003c\/td\u003e\n\u003ctd\u003e$40.2B premiums\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDental\/Vision\u003c\/td\u003e\n\u003ctd\u003e$1.2–1.5B op profit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eASO\u003c\/td\u003e\n\u003ctd\u003e$3.8B rev; ~9% margin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCorporate\u003c\/td\u003e\n\u003ctd\u003eDividend $3.90; net debt\/EBITDA ~2.6x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eCigna BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the final Cigna BCG Matrix you'll receive after purchase—no watermarks, no demo content—just a fully formatted, analysis-ready report designed for strategic clarity and professional use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748269011321,"sku":"cigna-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/cigna-bcg-matrix.png?v=1772206795","url":"https:\/\/matrixbcg.com\/products\/cigna-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}